Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Upregulation of Sox2 Following Saracatinib Treatment Contributes to a Resistant Phenotype in Colorectal Cancer Cells under Growth Factor-Supplemented Conditions.

Oncology research - 1 Jan 2026

Yoon Chanwoong, Na Euihyeon, Choi Min Joo, Yoon Sang-Pil

Abstract excerpt

Objective: Increased Src kinase activity is known to correlate with cancer progression and poor prognosis, indicating that Src plays a central role in cell migration and invasion. In this study, we investigated the effects of saracatinib, a Src kinase inhibitor, under anoikis-resistant conditions in colorectal cancer cells. Methods: Wild-type and 5-fluorouracil-resistance acquired SNU-C5 colorectal cancer cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzodioxoles
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Neoplastic Stem Cells

Share to Quinazolines

Share to SOXB1 Transcription Factors

Share to Spheroids, Cellular

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 42065072
DOI: 10.32604/or.2026.074140
PMCID: PMC13126402

Genes

EGFR
C5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Upregulation of Sox2 Following Saracatinib Treatment Contributes to a Resistant Phenotype in Colorectal Cancer Cells under Growth Factor-Supplemented Conditions.PMID 42065072Read ↗

Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line SpheroidsSemantic proximity Read ↗

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.Semantic proximity Read ↗

Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivatorSemantic proximity Read ↗

Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cellsSemantic proximity Read ↗

Aspirin Synergizes with Regorafenib to Reduce Growth of Colorectal CancerSemantic proximity Read ↗

Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes‐Associated Protein 1 Activation and Transient Expansion of Stem‐Like Cancer CellsSemantic proximity Read ↗

Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.Semantic proximity Read ↗

Gene Array and Fluorescence <i>In situ</i> Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal CancerSemantic proximity Read ↗

BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells.Semantic proximity Read ↗

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.Semantic proximity Read ↗

SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.Semantic proximity Read ↗

Acquired resistance to 5-fluorouracilviaHSP90/Src-mediated increase in thymidylate synthase expression in colon cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.